Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
Launched by G D SEARLE · Aug 30, 2001
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
SC-48334 is a chemical that prevents the biochemical actions of certain enzymes in the body, and recent studies have shown that it may also prevent the activity of HIV. The study will attempt to show whether SC-48334 can safely and effectively break the cycle of HIV infection in AIDS and advanced ARC by progressively eliminating HIV.
Six patients are enrolled sequentially into each of eight different dose levels and the drug is administered by mouth at least 60 minutes before meals according to the following schedule: Day 1: One-quarter of total assigned daily dose. Patients receive the do...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Concurrent Medication:
- Allowed:
- • Aerosolized pentamidine.
- • Nystatin.
- • Clotrimazole.
- • Topical acyclovir.
- Concurrent Treatment:
- Allowed:
- • Blood transfusions for = or \> grade 3 hemoglobin toxicity.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following conditions will be excluded:
- • Clinical significant diarrhea (\> 3 stools per day for \> 7 days without definable cause).
- • Active opportunistic infection, requiring ongoing therapy, at time of enrollment.
- • Any malignancy besides Kaposi's sarcoma, basal cell carcinoma, or squamous cell carcinoma unless the squamous cell carcinoma requires ongoing therapy.
- • Neurologic disease including dementia, peripheral neuropathy, myelopathy (CDC category IVb).
- Concurrent Medication:
- Excluded:
- • Antimetabolites.
- • Alkylating agents.
- • Drugs with known hepatic or bone marrow toxicity.
- • Patients with significant organ dysfunction will be excluded.
- Prior Medication:
- Excluded:
- • Antimetabolites.
- • Alkylating agents.
- * Excluded within 30 days of study entry:
- • Any investigational medication.
- • Drugs with anti-HIV activity.
- * Excluded within 90 days of study entry:
- • Ribavirin treatment.
- * Excluded within 6 months of study entry:
- • Cancer chemotherapy.
- Prior Treatment:
- Excluded within 6 months of study entry:
- • Radiation therapy.
- Patients must demonstrate the following clinical and laboratory findings:
- • AIDS or advanced AIDS related complex (ARC), according to Centers for Disease Control (CDC) category IV, excluding neurologic disease in IVb.
- • Ability to understand the terms of study participation.
- • Current use of illicit drugs or abuse of alcohol.
About G D Searle
G.D. Searle LLC, a subsidiary of Pfizer Inc., is a distinguished pharmaceutical company with a rich history in research and development. Focused on advancing innovative therapies across various therapeutic areas, G.D. Searle is committed to improving patient outcomes through rigorous clinical trials and a robust pipeline of products. The company emphasizes collaboration and integrity in its operations, ensuring adherence to the highest standards of safety and efficacy in its clinical research endeavors. G.D. Searle strives to address unmet medical needs, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
West Columbia, South Carolina, United States
Chicago, Illinois, United States
San Diego, California, United States
Miami, Florida, United States
Stanford, California, United States
Boston, Massachusetts, United States
Patients applied
Trial Officials
MS Hirsch
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials